Motor Neurone Disease
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder. It affects both upper and lower motor neurons and is characterised by a progressive degeneration and death of the anterior horn cells, cortico-spinal tracts and/or bulbar motor nuclei. The cause is unknown. There is an association between frontotemporal dementia (FTD) and ALS. ALS commonly occurs between the ages of 40 and 60 years, and males are affected more than females. The disease is relentlessly progressive. The median life span is about 4 years. Most with ALS will die from respiratory failure. Symptoms of bulbar involvement usually imply a rapid course usually with survival of a year. There is no cure, and medical care is mainly palliation and involves a multidisciplinary approach.
KeywordsMotor neurone disease Amyotrophic lateral sclerosis Frontotemporal dementia (FTD) Riluzole El Escorial criteria Awaji criteria
- 11.Xue LY. The useof EMG/NCS in neuromuscular disorders. New Engl Neurological Assoc.PC 2013. www.nenero.com/theuseof_-emgries_in_neuromuscular_disorders accessed 10 May 2016.
- 13.Armon C. Amyotrophic lateral sclerosis workshop.Medscape. emedicine.medscape.com/article/1170097-workshop. accessed 10 May 2016.
- 14.Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. ALS other Motor Neuron Disord. 2000:1:293–299.Google Scholar
- 15.Dengler R. Diagnostic criteria of amyotrophic lateral sclerosis.(ALS). Romanian J Neurol. 2010;9(4):165–8.Google Scholar
- 17.Leigh N, Lloyd CM, Ray-Chaudhuri K, Motor Neurone Disease. In: Wiles CM ed Management of neurological diseases London. BMJ publishing Group 195;241:71.Google Scholar
- 24.Van Der Steen I, Van Den Berg Jan-P, Buskeus E, Lindeman E, Van Den Berg LH. The costs of amyotrophic lateral sclerosis, according to type of care. J ALS 2009;10(1): http://www.tandfonline.com/doi/abs/10.1080/1748296082103131?journalCode+iafd19 accessed on 9 November 2015.
- 25.Korner S, Hendricks M, Kollewe K, Zapf A, Dengler R, Silani V, et al. Weight loss dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS) impact on quality of life and therapeutic options. BMC Neurology. 2013;13:84. https://doi.org/10.1186/1471-23-77-13-84.CrossRefPubMedPubMedCentralGoogle Scholar